



## PRESS RELEASE

May 6, 2024

# Ziccum CEO Analyst video interview: Q1, 2024 highlights

**Watch Ziccum CEO Ann Gidner in a comprehensive interview with analyst Jonathan Furelid on the highlights of Ziccum's Q1 2024 report and the company's current and coming status.**

CEO Ann Gidner provides investors with updates and insights on its new data readouts in mRNA /LNP, the status of Ziccum's current partner projects and business dialogues, as well as technology development with significantly strengthened IP plus two new appointments within BD and Finance.

Watch the interview [here](#).

**For more information about Ziccum, please contact:**

---

Ann Gidner,  
CEO Ziccum  
Mail: [gidner@ziccum.com](mailto:gidner@ziccum.com)  
Mobile: +46 722140141

Fredrik Sjövall,  
Chairman of the Board, Ziccum AB  
Mail: [sjovall@ziccum.com](mailto:sjovall@ziccum.com)  
Mobile: +46 706 45 08 75

Ziccum's Certified Adviser is  
Carnegie Investment Bank AB (publ).  
Follow us on <https://eucaps.com/ziccum>

## About Ziccum

---

Ziccum is developing LaminarPace™, a unique drying method for biopharmaceuticals and vaccines based on mass transfer, not heat transfer. The technology is offered by licensing to vaccine and biologics developers and manufacturers in the global pharmaceutical industry. By reducing drying stress to the active ingredient, LaminarPace™ uniquely enables particle-engineered, thermostable dry powder biopharmaceuticals which can be easily handled and transported and are highly suitable for novel administration routes. The technology has been successfully applied to mRNA, peptides, proteins, antibodies, lipids and enzymes as well as excipients and adjuvants, and is well suited for industrial application. Ziccum is listed on the Nasdaq First North Growth Market.

---

Attachments

---

[Ziccum CEO Analyst video interview: Q1, 2024 highlights](#)